TY - JOUR
T1 - pH-sensitive polymer-modified liposome-based immunity-inducing system
T2 - Effects of inclusion of cationic lipid and CpG-DNA
AU - Yoshizaki, Yuta
AU - Yuba, Eiji
AU - Sakaguchi, Naoki
AU - Koiwai, Kazunori
AU - Harada, Atsushi
AU - Kono, Kenji
N1 - Funding Information:
This work was supported by Grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture in Japan (15H03024, 26242049). Y. Yoshizaki thanks the research fellowship of Japan Society for the Promotion of Science (15J12180).
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/10
Y1 - 2017/10
N2 - Efficient vaccine carriers for cancer immunotherapy require two functions: antigen delivery to dendritic cells (DCs) and the activation of DCs, a so-called adjuvant effect. We previously reported antigen delivery system using liposomes modified with pH-sensitive polymers, such as 3-methylglutarylated hyperbranched poly(glycidol) (MGlu-HPG), for the induction of antigen-specific immune responses. We reported that inclusion of cationic lipids to MGlu-HPG-modified liposomes activates DCs and enhances antitumor effects. In this study, CpG-DNA, a ligand to Toll-like receptor 9 (TLR9) expressing in endosomes of DCs, was introduced to MGlu-HPG-modified liposomes containing cationic lipids using two complexation methods (Pre-mix and Post-mix) for additional activation of antigen-specific immunity. For Pre-mix, thin membrane of lipids and polymers were dispersed by a mixture of antigen/CpG-DNA. For Post-mix, CpG-DNA was added to pre-formed liposomes. Both Pre-mix and Post-mix delivered CpG-DNA to DC endosomes, where TLR9 is expressing, more efficiently than free CpG-DNA solution did. These liposomes promoted cytokine production from DCs and the expression of co-stimulatory molecules in vitro and induced antigen-specific immune responses in vivo. Both Pre-mix and Post-mix exhibited strong antitumor effects compared with conventional pH-sensitive polymer-modified liposomes. Results show that inclusion of multiple adjuvant molecules into pH-sensitive polymer-modified liposomes and suitable CpG-DNA complexation methods are important to design potent vaccine carriers.
AB - Efficient vaccine carriers for cancer immunotherapy require two functions: antigen delivery to dendritic cells (DCs) and the activation of DCs, a so-called adjuvant effect. We previously reported antigen delivery system using liposomes modified with pH-sensitive polymers, such as 3-methylglutarylated hyperbranched poly(glycidol) (MGlu-HPG), for the induction of antigen-specific immune responses. We reported that inclusion of cationic lipids to MGlu-HPG-modified liposomes activates DCs and enhances antitumor effects. In this study, CpG-DNA, a ligand to Toll-like receptor 9 (TLR9) expressing in endosomes of DCs, was introduced to MGlu-HPG-modified liposomes containing cationic lipids using two complexation methods (Pre-mix and Post-mix) for additional activation of antigen-specific immunity. For Pre-mix, thin membrane of lipids and polymers were dispersed by a mixture of antigen/CpG-DNA. For Post-mix, CpG-DNA was added to pre-formed liposomes. Both Pre-mix and Post-mix delivered CpG-DNA to DC endosomes, where TLR9 is expressing, more efficiently than free CpG-DNA solution did. These liposomes promoted cytokine production from DCs and the expression of co-stimulatory molecules in vitro and induced antigen-specific immune responses in vivo. Both Pre-mix and Post-mix exhibited strong antitumor effects compared with conventional pH-sensitive polymer-modified liposomes. Results show that inclusion of multiple adjuvant molecules into pH-sensitive polymer-modified liposomes and suitable CpG-DNA complexation methods are important to design potent vaccine carriers.
KW - Adjuvant
KW - Cancer immunotherapy
KW - Cationic lipid
KW - CpG-DNA
KW - Dendritic cell
KW - pH–sensitive liposome
UR - http://www.scopus.com/inward/record.url?scp=85022049459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85022049459&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2017.07.001
DO - 10.1016/j.biomaterials.2017.07.001
M3 - Article
C2 - 28704679
AN - SCOPUS:85022049459
SN - 0142-9612
VL - 141
SP - 272
EP - 283
JO - Biomaterials
JF - Biomaterials
ER -